Keywords: Breast, Breast
Motivation: Breast cancer (BC) with low HER2 expression (HER2-low) may benefit from newly developed antibody-drug couplings, but identification of HER2-low by non-invasive imaging methods remains challenge.
Goal(s): To assess whether DWI and amide proton transfer weighted imaging (APTWI) can help distinguish HER2-low from HER2 zero- (HER2-zero) and over-expressions (HER2-oe) in BC.
Approach: 56 HER2-oe, 78 HER2-low, and 39 HER2-zero BC patients were enrolled. ADC and MTRasym(3.5ppm) were compared between the three groups. The identification ability was assessed by ROC analysis.
Results: MTRasym (3.5ppm) and ADC are effective predictors for diagnosing HER2 expression levels, exhibiting superior predictive performance when utilized in combination.
Impact: APTWI could be used as non-invasive biomarker for identifying HER2-zero,HER2-low, and HER2-oe. The application of APTWI would be beneficial for guiding treatment selection and dynamically monitoring HER2 expressing level throughout the course of treatment for BC patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords